Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.

Protein farnesyltransferase (FTase) catalyzes an essential posttranslational lipid modification of more than 60 proteins involved in intracellular signal transduction networks. FTase inhibitors have emerged as a significant target for development of anticancer therapeutics and, more recently, for the treatment of parasitic diseases caused by protozoan pathogens, including malaria (Plasmodium falciparum). We present the X-ray crystallographic structures of complexes of mammalian FTase with five inhibitors based on an ethylenediamine scaffold, two of which exhibit over 1000-fold selective inhibition of P. falciparum FTase. These structures reveal the dominant determinants in both the inhibitor and enzyme that control binding and selectivity. Comparison to a homology model constructed for the P. falciparum FTase suggests opportunities for further improving selectivity of a new generation of antimalarial inhibitors.

[1]  W. R. Bishop,et al.  Lipid posttranslational modifications. Farnesyl transferase inhibitors. , 2006, Journal of lipid research.

[2]  D. Chakrabarti,et al.  Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. , 2005, Angewandte Chemie.

[3]  P. Rathod,et al.  Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum* , 2005, Journal of Biological Chemistry.

[4]  W. R. Bishop,et al.  Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[5]  Sebastian Maurer-Stroh,et al.  Protein prenyltransferases , 2003, Genome Biology.

[6]  H. Hellinga,et al.  The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Casey,et al.  Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. , 2003, Biochemistry.

[8]  P. Rathod,et al.  Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. , 2007, Molecular and biochemical parasitology.

[9]  P. Casey,et al.  Structure of mammalian protein geranylgeranyltransferase type‐I , 2003, The EMBO journal.

[10]  D. Chakrabarti,et al.  In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. , 2004, Bioorganic & medicinal chemistry.

[11]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[12]  A. D. Rodrigues,et al.  3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. , 2002, Journal of medicinal chemistry.

[13]  P. Casey,et al.  Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. , 1995, Biochemistry.

[14]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[15]  Michael J E Sternberg,et al.  Exploring the extremes of sequence/structure space with ensemble fold recognition in the program Phyre , 2008, Proteins.

[16]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[17]  L. Beese,et al.  Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. , 2004, Biochemistry.

[18]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[19]  P. Casey,et al.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. , 2000, Structure.

[20]  P. Casey,et al.  Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. , 1998, Biochemistry.

[21]  P. Casey,et al.  Substrate Binding Is Required for Release of Product from Mammalian Protein Farnesyltransferase* , 1997, The Journal of Biological Chemistry.

[22]  P. Casey,et al.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. , 2004, Journal of molecular biology.

[23]  C. Fierke,et al.  Mechanistic studies of rat protein farnesyltransferase indicate an associative transition state. , 2000, Biochemistry.

[24]  P. Casey,et al.  Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. , 1996, The Biochemical journal.

[25]  D. Chakrabarti,et al.  Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. , 2006, Journal of medicinal chemistry.

[26]  David C. Richardson,et al.  MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes , 2004, Nucleic Acids Res..

[27]  D. Chakrabarti,et al.  Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase , 2007, Antimicrobial Agents and Chemotherapy.

[28]  P. Casey,et al.  Conversion of protein farnesyltransferase to a geranylgeranyltransferase. , 2006, Biochemistry.

[29]  Michalis V. Karamouzis,et al.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.

[30]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[31]  P. Cassidy,et al.  Yeast protein farnesyltransferase: steady-state kinetic studies of substrate binding. , 1995, Biochemistry.

[32]  Stephen B. Long,et al.  Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.

[33]  L. Beese,et al.  Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I Published, JLR Papers in Press, February 13, 2006. , 2006, Journal of Lipid Research.

[34]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[35]  L. Beese,et al.  Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. , 2004, Biochemistry.

[36]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[37]  P. Casey,et al.  High level expression of mammalian protein farnesyltransferase in a baculovirus system. The purified protein contains zinc. , 1993, The Journal of biological chemistry.

[38]  M. Gelb,et al.  Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation Published, JLR Papers in Press, December 7, 2005. , 2006, Journal of Lipid Research.

[39]  P. Casey,et al.  H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate. , 1998, Biochemistry.

[40]  L. Beese,et al.  Structure of Protein Geranylgeranyltransferase-I from the Human Pathogen Candida albicans Complexed with a Lipid Substrate* , 2008, Journal of Biological Chemistry.